Kamrin Macki
Nurse Practitioner · Grand Forks, NDNPI 1073605408
Payments from drug & device makers
Across 13 payments — averaging $58.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$284
- Phathom Pharmaceuticals, Inc.$141
- E.r. Squibb & Sons, L.L.C.$108
- Gilead$55
- Sanofi$55
- Ardelyx, Inc.$55
- plus $63 from 2 others
What the payments were for
- Food & beverage$68690%
- Education$7610%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 4 | $284 |
| Phathom Pharmaceuticals, Inc. | 2 | $141 |
| E.r. Squibb & Sons, L.L.C. | 2 | $108 |
| Gilead | 1 | $55 |
| Sanofi | 1 | $55 |
| Ardelyx, Inc. | 1 | $55 |
| Ferring Pharmaceuticals Inc. | 1 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
How this compares
$762 in reported general payments places this provider in the 80th percentile of 455 nurse practitioner providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trientine Hcl | 21 | $437,253 |
| StelaraUstekinumab | 13 | $350,160 |
| Humira(Cf) PenAdalimumab | 22 | $278,253 |
| XifaxanRifaximin | 62 | $206,730 |
| Humira PenAdalimumab | 13 | $85,947 |
| CreonLipase/Protease/Amylase | 31 | $71,942 |
| Mesalamine | 57 | $21,402 |
| Alosetron Hcl | 43 | $21,391 |
| LinzessLinaclotide | 30 | $19,636 |
| Ursodiol | 100 | $17,639 |
| Colestipol Hcl | 77 | $6,429 |
| Balsalazide Disodium | 32 | $4,891 |
| Mesalamine ErMesalamine | 21 | $4,864 |
| Dexlansoprazole DrDexlansoprazole | 15 | $4,506 |
| Azathioprine | 70 | $3,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $284 | $350,16013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 455 nurse practitioner providers in North Dakota.
Other nurse practitioner in Grand Forks
- Nicole MorganGrand Forks$7K
- Marlie BorowiczGrand Forks$5K
- Caroline SchroederGrand Forks$3K
- Wade OlsonGrand Forks$3K
- Jennifer LaframboiseGrand Forks$2K
- Melissa HayesGrand Forks$1K
- Emily GreensteinFargo$271K
- Sarah MatchaFargo$17K
- Jana SuderFargo$16K
- Lisa ClairmontBismarck$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.